Global Blood Therapeutics Inc.

NASDAQ:GBT   3:59:47 PM EDT
43.17
+0.88 (+2.08%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.68B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$43.45 Million
Adjusted EPS-$1.01
See more estimates
10-Day MA$41.66
50-Day MA$43.33
200-Day MA$51.88
See more pivots

Global Blood Therapeutics Inc. Stock, NASDAQ:GBT

181 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.741.7700
Number of Employees: 389

Description

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.